Authors:
DEACON CF
KNUDSEN LB
MADSEN K
WIBERG FC
JACOBSEN O
HOLST JJ
Citation: Cf. Deacon et al., DIPEPTIDYL PEPTIDASE-IV RESISTANT ANALOGS OF GLUCAGON-LIKE PEPTIDE-1 WHICH HAVE EXTENDED METABOLIC STABILITY AND IMPROVED BIOLOGICAL-ACTIVITY, Diabetologia, 41(3), 1998, pp. 271-278
Authors:
DEACON CF
RIBEL U
ROED B
HOLM HBJ
HOLST JJ
CARR RD
Citation: Cf. Deacon et al., GLUCAGON-LIKE PEPTIDE-1 (9-36)AMIDE DOES NOT DESENSITIZE CONSCIOUS PIGS TO THE ANTI-HYPERGLYCEMIC ACTION OF GLP-1, Diabetologia, 41, 1998, pp. 72-72
Citation: Cf. Deacon et al., DIPEPTIDYL-PEPTIDASE-IV INHIBITION POTENTIATES THE INSULINOTROPIC EFFECT OF GLUCAGON-LIKE PEPTIDE-1 IN THE ANESTHETIZED PIG, Diabetes, 47(5), 1998, pp. 764-769
Citation: Jj. Holst et Cf. Deacon, INHIBITION OF THE ACTIVITY OF DIPEPTIDYL-PEPTIDASE-IV AS A TREATMENT FOR TYPE-2 DIABETES, Diabetes, 47(11), 1998, pp. 1663-1670
Authors:
HOLST JJ
HANSEN L
ORSKOV C
WOJDEMANN M
WETIERGREN A
DEACON CF
Citation: Jj. Holst et al., GLP-1 (7-36AMIDE) IS TRANSFORMED BY DIPEPTIDYL PEPTIDASE-IV IN THE CAPILLARIES SUPPLYING THE L-CELLS INTO GLP-1 (9-36AMIDE), WHICH ANTAGONIZES THE GASTROINTESTINAL EFFECTS OF GLP-1, Diabetes, 47, 1998, pp. 115-115
Citation: Cf. Deacon et al., DIPEPTIDYL PEPTIDASE-IV INHIBITION POTENTIATES THE INSULINOTROPIC EFFECT OF GLUCAGON-LIKE PEPTIDE-1, Diabetes, 47, 1998, pp. 268-268
Citation: Jj. Holst et al., THE GLP-1 RECEPTOR ANTAGONIST, GLP-1 (9-36AMIDE), IS A PRIMARY PRODUCT OF THE INTESTINAL L-CELL, Diabetologia, 40, 1997, pp. 98-98
Authors:
PRIDAL L
DEACON CF
KIRK O
CHRISTENSEN JV
CARR RD
HOLST JJ
Citation: L. Pridal et al., GLUCAGON-LIKE PEPTIDE-1(7-37) HAS A LARGER VOLUME OF DISTRIBUTION THAN GLUCAGON-LIKE PEPTIDE-1(7-36)AMIDE IN DOGS AND IS DEGRADED MORE QUICKLY IN-VITRO BY DOG PLASMA, European journal of drug metabolism and pharmacokinetics, 21(1), 1996, pp. 51-59
Authors:
DEACON CF
PRIDAL L
KLARSKOV L
OLESEN M
HOLST JJ
Citation: Cf. Deacon et al., GLUCAGON-LIKE PEPTIDE-1 UNDERGOES DIFFERENTIAL TISSUE-SPECIFIC METABOLISM IN THE ANESTHETIZED PIG, American journal of physiology: endocrinology and metabolism, 34(3), 1996, pp. 458-464
Citation: Cf. Deacon et al., DEGRADATION OF GLUCAGON-LIKE PEPTIDE-1 BY HUMAN PLASMA IN-VITRO YIELDS AN N-TERMINALLY TRUNCATED PEPTIDE THAT IS A MAJOR ENDOGENOUS METABOLITE IN-VIVO, The Journal of clinical endocrinology and metabolism, 80(3), 1995, pp. 952-957
Citation: Cf. Deacon et al., DIFFERENTIAL ORGAN-SPECIFIC METABOLISM OF GLUCAGON-LIKE PEPTIDE-1 IN THE ANESTHETIZED PIG, Diabetologia, 38, 1995, pp. 167-167
Authors:
DEACON CF
NAUCK MA
TOFTNIELSEN M
PRIDAL L
WILLMS B
HOLST JJ
Citation: Cf. Deacon et al., BOTH SUBCUTANEOUSLY AND INTRAVENOUSLY ADMINISTERED GLUCAGON-LIKE PEPTIDE-I ARE RAPIDLY DEGRADED FROM THE NH2-TERMINUS IN TYPE-II DIABETIC-PATIENTS AND IN HEALTHY-SUBJECTS, Diabetes, 44(9), 1995, pp. 1126-1131
Citation: Hbc. Aptel et al., ATRIAL-NATRIURETIC-PEPTIDE IN THE MILAN HYPERTENSIVE RAT AND THE MILAN NORMOTENSIVE RAT - PLASMA-CONCENTRATION AND BINDING TO RENAL GLOMERULI IN YOUNG, ADULT AND AGED RATS, Journal of hypertension, 12(11), 1994, pp. 1209-1215
Citation: Hbc. Aptel et al., INTERACTIONS OF ATRIAL-NATRIURETIC-PEPTIDE WITH A7R5 CELLS, Biochemical and biophysical research communications, 204(3), 1994, pp. 1286-1291